GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results: Patrick Marcellin, Hopital Beaujon, Clichy France; Ting-Tsung Chang, National Cheng Kung Univ Hospital, Tainan Taiwan; Seng Gee Lim, National University Hospital, Singapore Singapore; Myron J Tong, Huntington Memorial Hospital, Pasadena, CA; William Sievert, Monash Medical Centre, Clayton, Victoria Australia; Mitchell Shiffman, McGuire VAMC, Richmond, VA; Lennox Jeffers, University of Miami, Miami, FL; Zack Goodman, Armed Forces Institute of Pathology, Washington, DC; Jia Ma, Anant Jain, John Fry, Carol L Brosgart, Gilead Sciences, Foster City, CA